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Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that infects nearly 
95% of the world’s population. EBV is closely associated with many diseases, most 
commonly with infectious mononucleosis, though the virus is also linked to different 
types of cancer such as Burkitt’s lymphoma, other non-Hodgkin’s lymphomas, 
Hodgkin’s lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. Pesticides are 
globally used residentially and agriculturally and have been a topic of discussion with 
regard to their effects on human health. Chlorpyrifos, a neurotoxic acetylcholinesterase 
inhibitor, has been banned for residential use in the United States since 2000. However, it 
is still one of the most commonly used organophosphate pesticides for agriculture. 
Epidemiological case studies have investigated potential associations with individuals 
who have occupational organophosphate exposure (such as farmers) and certain types of 
cancer. However, many of these studies have inconclusive or conflicting results. An 
understudied area of investigation is interactions of ubiquitous human viruses and other 
environmental factors, such as pesticides, that may promote or further exacerbate adverse 
human health issues. It is equally important to understand if environmental factors affect 
virus-host interactions and by what cellular mechanisms. This dissertation investigates 
the effects of chlorpyrifos and its active metabolite, chlorpyrifos-oxon, on EBV-host 
interactions; specifically exploring the effects on EBV and B-lymphocyte replication. 
Findings suggest that chlorpyrifos and chlorpyrifos-oxon exposure produce low levels of 
oxidative stress and DNA damage to B-lymphocyte cells to initiate cellular signaling 
cascades to induce cell cycle arrest. Additionally, we find that pesticide exposure affects 
EBV lytic replication and latency in addition to cellular targets that are involved with 
viral and host-cell replication and regulatory functions. Overall, our results show that the 
presence of EBV appears to have a protective response to cells under cytotoxic stress. 
Findings from this study will contribute to a better understanding of EBV-host biology 
and interactions in the presence of exogenous environmental factors that may be harmful 
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INTRODUCTION AND BACKGROUND 
 
1. Introduction 
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that infects nearly 
95% of the world’s population.1 EBV is most commonly linked with infectious 
mononucleosis, which is characterized by fatigue, swollen lymph nodes, fever, sore 
throat, body aches, and rash. The virus is also associated with different types of cancer 
such as Burkitt’s lymphoma, other non-Hodgkin’s lymphomas, Hodgkin’s lymphoma, 
gastric carcinoma, and nasopharyngeal carcinoma.1 Pesticide use is a worldwide practice 
residentially and agriculturally and has been a topic of discussion with regard to potential 
adverse effects to humans. Chlorpyrifos is a type of organophosphate pesticide that is 
neurotoxic to insects.2–5 Although certain organophosphates are banned or heavily 
restricted for residential use, chlorpyrifos is still used (with restrictions) in 
agriculture/commercial farming.4,6–12 Epidemiological case studies have suggested a 
connection between pesticide exposure (especially for farmers or other individuals who 
have occupational exposure) and certain types of cancer including non-Hodgkin’s 
lymphoma.7–9,13 In contrast, meta-analysis studies (using patient data, farmer/worker 
interviews, and blood and urine sample analysis), also report there is little to no direct 




An understudied area is the investigation of viruses interacting with other 
environmental factors, such as pesticides, to further promote adverse human health 
issues. However, it is equally important to understand the basic research and science 
aspects of environmental factors effects on virus-host interactions.  
2. Background 
2.1 Epstein-Barr Virus 
Epstein-Barr virus (EBV) is a well-studied, double stranded DNA (Baltimore 
class I), gamma human herpesvirus (HHV-4) that infects over 95% of the world’s 
population.1 EBV has important research implications and impact due to its global 
presence in human populations. EBV is primarily orally transmitted through the exchange 
of saliva (kissing, sharing food or drink, using the same utensils), but the virus can also 
be transmitted through blood transfusions, organ transplants, and sexual contact.1 Initial 
infection of the virus typically occurs early in life with little (cold and flu like) to no 
symptoms, while if infected at adolescence or later, individuals may observe common 
symptoms of infectious mononucleosis.20,21 Once infected with the virus, the individual is 
a carrier of the virus for life. Most commonly known to cause infectious mononucleosis, 
EBV is also widely associated with cancers such as Hodgkin’s and non-Hodgkin’s 
lymphoma, Burkitt’s lymphoma (a type of non-Hodgkin’s lymphoma), EBV-associated 
gastric carcinoma, and nasopharyngeal carcinoma.1 Immunocompromised individuals are 
more prone to acquire these malignancies associated with EBV. It is well established that 
cancer and tumor formation from EBV infection involve the latency state of infected cells 




2.2 EBV Infection and Replication 
EBV has two mechanisms of replication, lytic replication and latency. Lytic 
replication is the process of producing new virions in host epithelial and B-lymphocyte 
cells and is a key step in virus pathogenesis.22–25 Once the host cell is initially infected 
with EBV (primary infection), the virus can either infect B-lymphocyte cells and enter 
latency and/or infect neighboring epithelial cells where the virus continues lytic 
replication.1,26–29 EBV glycoproteins attach to host cell receptors or integrins and enter 
the host cell through glycoprotein mediated fusion (epithelial cells) or endocytosis (B-
lymphocyte cells).1 For B cells, EBV glycoprotein gp350 binds to the host receptor 
CR2/CD21 before being endocytosed.1,29,30 Other important EBV glycoproteins 
necessary for infection include gB that mediates fusion of the virus to the B cell 
membrane, and the gHgL and gp42 complex that interacts with human leukocyte antigen 
(HLA) class II  and aids in B cell infection.28,30–33 EBV entry into epithelial cells on the 
other hand is still an area that researchers continue to explore. From what we know now, 
epithelial cells do not utilize endocytosis, but fusion for viral entry via BMRF2 and 
integrins for binding, then gHgL and gB for membrane fusion.1,32,34 It is important to note 
that gp42 is an important glycoprotein that mediates and regulates cell type tropism for 
EBV.1,30,31,33,34 
After attachment, the EBV viral capsid enters the cytoplasm and is transported to 
the nucleus via microtubules.1 Once in the host cell nucleus, the EBV genome is released 
and lytic replication resumes.1 Three types of viral genes and proteins are transcribed and 




early genes and gene products are transactivators that regulate and promote synthesis of 
EBV early genes and proteins which are associated with viral replication.1,35–37 EBV late 
genes and proteins are involved with structural and survival characteristics of EBV, such 
as capsid formation and gene products that are involved with evasion of the host’s 
immune system.1,27,37,38 
Reactivation of the lytic cycle from latency in B cells is important for maintaining 
production of new virions and contributing to EBV pathogenesis.1,39,40 Various factors 
can contribute to reactivation of lytic replication including DNA damage and chemical 
agents like sodium butyrate (NaB) and12-0-tetradecanoyl phorbol-13-acetate (TPA).24 
Production of new virions can advance infection of host B cells to become latent which 
can lead to carcinogenesis through the expression of latency genes and proteins.1,39,40 
Thus, the production of new EBV virions or the reactivation of lytic replication is 
necessary for the production of new latent cells. 
2.3 EBV Latency and EBV Associated Cancers 
After primary infection in epithelial cells, EBV can infect naïve B cells (cells that 
have not been exposed to antigens).1 B cells infected with EBV transform to become 
memory, immortalized B cells where the EBV genome circularizes and the cells replicate 
as lymphoblastoid cell lines (LCLs).1,41–44 B-lymphocyte cells infected with EBV that 
express genes for latent proteins may lead to cancers like non-Hodgkin’s Lymphoma 
(such as Burkitt’s lymphoma) and immunodeficiency dependent lymphomas.1,23,45–47 
EBV latency has three programs (I, II, and III) and within these programs different types 




cancers.1,23,46,48 The main types of latency gene products include: EBV nuclear antigens 
(EBNAs), EBV latent membrane proteins (LMPs), EBV-encoded small RNAs (EBERs), 
and miRNAs.1 These are important for maintenance of the viral genome episome, 
replication, and enhancement of cell survival (EBNA-1)49,50;  B cell transformation 
(EBNA- 3A/3C and LMP-1)51; oncogene, activator to oncogenic signaling pathway, and 
a tumor necrosis factor receptor (LMP1).41,44,52  EBNA-1 is expressed in all latency 
programs, while other latency protein expression is dependent on the program and 
progression of certain EBV-associated diseases (Table 1).  
 
 
Disease  EBV Genes/Proteins 
Expressed 
Latency Program 
Burkitt’s Lymphoma EBNA-1 1 



























Low levels of latent viral proteins allow EBV to evade an immune response by 
the host. Latency of EBV mainly occurs in B-lymphocyte cells and can occur soon after 
infection or can occur after lytic replication.1,38 EBV can still replicate while dormant, 
however, mechanistically, replication occurs through the host cells’ cellular division 
rather than viral replication mechanisms.1,27 
2.4 EBV-Host Interactions  
 It is well known that EBV and other herpesviruses utilize and hijack host 
mechanisms/signaling pathways for replication and survival.38,53 EBV protein expression 
can either activate or disrupt certain cellular pathways/cascades or conversely the activity 
of a particular pathway might initiate EBV protein activity. Some examples of this 
include 1) EBV lytic replication is inhibited by the inactivation of mTORC154 and YY1 
regulation,24,55 2) activation of EBV lytic proteins BZLF1 and BMRF1 induce activation 
of MAPKs like p38 and JNK56 and the PI3K signaling cascade,57 3) ATM-mediated cell 
cycle signaling is induced with EBV lytic replication,58 4) latent EBV protein LMP1 
disrupts NF-ĸB regulation to transform lymphocyte cells and to promote cell 
proliferation,38,59 and 5) LMP2 activates the Ras/PI3K-AKT constitutively for B cell 
transformation.60  
2.5 Neuronal and Immune Cell Acetylcholine and Acetylcholinesterase  
Acetylcholine is a neurotransmitter that is typically found within the central 
nervous system at synapses. Choline acetyltransferase synthesizes acetylcholine from 
acetyl-CoA and choline at the presynaptic terminal of neuronal cells. Once released to the 




muscarinic receptors (G-protein-coupled receptor/integral membrane protein) on the post-
synaptic cell where acetylcholinesterase AChE breaks down acetylcholine (to choline and 
acetate) (Fig.1).61 Choline can then reenter the presynaptic terminal to start synthesis with 
acetyl-CoA and choline acetyltransferase (Fig.1). AChE typically is stored in vesicles 
near acetylcholine receptors in the synaptic cleft (space between the presynaptic terminal 
and postsynaptic cell) of the cytoplasm of neurons.62 Although acetylcholine is normally 
found in neuronal cells, it can also be found in a variety of mammalian immune cells, 
including human lymphocytes.63–65 Like neuronal cells, lymphocyte nicotinic and 
muscarinic receptors are present and acetylcholine is synthesized also by choline 
acetyltransferase or carnitine acetyltransferase.61,64,66–68 Studies have shown that only T-
cells synthesize choline acetyltransferase, and not B cells; however, other studies have 
found that B cells do produce choline acetyltransferase.62,68,69 It has also been established 
that both T and B cells express AChE mRNA.64 Based on different studies investigating 
non-neuronal acetylcholine activity, it appears that in immune cells, like lymphocytes, 
acetylcholine receptors are found on the cell membranes where extracellular 
acetylcholine can bind to the receptor. From there, AChE can hydrolyze acetylcholine to 
acetate and choline, where choline and acetyl-CoA within the cell can form acetylcholine 









Figure 1. Overview of Synthesis and Regulation of Acetylcholine at Synapses. 
Acetylcholine is typically most associated at the synapses of neurons. Acetylcholine is 
synthesized in the presynaptic terminal by choline and acetyl-CoA with choline 
acetyltransferase (CAT or ChAT). Newly formed acetylcholine is packaged in vesicles 
and gets transferred to the synaptic cleft (space between the pre and postsynaptic cells) 
where it will bind to acetylcholine receptors (AChRs). Acetylcholinesterase (AChE) 
will then breakdown acetylcholine to choline and acetate. Choline will then get 




2.6 Organophosphates and Pesticide Use 
Organophosphates (such as chlorpyrifos) are commonly used as pesticides for 
residential and agricultural use. Specifically, they act as neurotoxic insecticides and 
function as AChE inhibitors.2,4,12,70–73 Organophosphates are irreversible inhibitors that 
prevents AChE from hydrolyzing acetylcholine. This in turn prevents the breakdown of 
acetylcholine (to choline and acetate) and results in acetylcholine accumulation causing 
overstimulation, thus creating issues with neurotransmission, and eventual 
neurotoxicity.2,4,12,70–73  
Organophosphate poisoning can lead to sweating, muscle weakness, involuntary 
muscle movements, excessive production of saliva, and excessive constriction of the 
pupil.71 More severe organophosphate poisoning can lead to extreme health conditions 
like loss of consciousness, failure of the respiratory system, convulsions, and in the some 
cases, death.4,71,72 
The main route of absorption is through ingestion or inhalation, but 
organophosphates can also be absorbed dermally depending upon the organophosphate as 
they are lipophilic.4 Many organophosphates are biotransformed to a more toxic form, 
such as oxons, though this form is more likely to degrade freely.3,4,74,75 In humans, 
biotransformation occurs mainly in the liver through phase I and phase II reactions.70,76,77 
In vivo, organophosphates become transformed to their active metabolite through a 
variety of different process such as oxidation, desulfuration, hydroxylation, and other 
reactions not related to oxidation (Fig.2).70,75,78,79 Detoxification of organophosphates 




dearylation, and hydrolytic enzymes (Fig.2).70,71,73,74,79,80 Other characteristics of 
organophosphates include being lipophilic, which allows easy absorption to target insects 
and also the ability to be easily stored in fat cells in humans, causing delayed neuropathy, 
and depending on the organophosphate, being prone to having additive effects when 
another organophosphate is present and absorbed.4,70,72,81 Prolonged exposure to humans 
may potentially cause dysregulation in important cellular signaling pathways.  
Chlorpyrifos (CPF) is an example of a commonly used organophosphate in 
agriculture. As of the early 2000s, there were 10 million pounds of CPF applied to crops 
each year and of those crops, corn used CPF the most at 5.5 million pounds of CPF.11,82 
Over the years, CPF and other organophosphates have been heavily regulated, banned, or 
phased out by the Environmental Protection Agency (EPA).3,4,83 In the US, CPF is no 
longer allowed for residential use, but is allowed for agricultural use, and has undergone 
several reevaluations and human health risk assessments by the EPA,83 with the most 
recent in 2016.84  
CPF toxicity is caused through the irreversible binding of the active metabolite 
chlorpyrifos-oxon (CPO) to AChE.85–87 CPO is the oxidized metabolite of CPF and is 
known to be more toxic than the parent compound.87 CPF to CPO metabolism is 





As mentioned with general organophosphate metabolism, CPF is detoxified by 
dearylation (CYP450 mediated) or hydrolysis to form the non-toxic 3, 5, 6-trichloro-2-
pyridinol or TCP. The TCP metabolite is often used to detect CPF exposure in blood or 
urine samples (Fig.2).74,85,87,89 
 
 
Figure 2. Biotransformation of Chlorpyrifos. Chlorpyrifos can undergo oxidative 
desulfuration to form its active metabolite, chlorpyrifos-oxon. Alternatively, 
Chlorpyrifos can also undergo a detoxifying step involving dearylation or hydrolysis 
to form the metabolites, 3,5,6-trichloropyridinol (TCP) and diethylthiophosphate. 
Chlorpyrifos-oxon also undergoes a detoxifying step via paraoxanase to form TCP 




2.7 Cell Cycle Regulation and Cancer  
 The cell cycle is an important cellular mechanism necessary for chromosome 
replication and segregation. This process includes mitosis and interphase (G1, S, and G2 
phases). During G1 phase, the cell awaits a signal to initiate entry into S phase, and 
prepares for DNA replication. S phase is the actual step where DNA is replicated, and 
during G2 phase the cell is preparing for the newly synthesized DNA to undergo mitosis. 
During mitosis the chromosomes, as well as all other cellular components, are 
segregated; this stage is immediately followed by cytokinesis.  
The cell cycle is regulated and controlled by many different regulatory proteins, 
however cyclin dependent kinases (CDKs) are key in driving cell cycle progression (and 
also arrest).90,91 There are nine known CDKs, of which five are necessary and activated 
during G1 (CDK2, 4, and 6), S (CDK2) or G2 (CDK1) phase.90,92,93 Cyclins binding to 
CDKs are also necessary for cell cycle progression and regulation, especially for 
transitions and entry from one phase to another (such as G1 to S transition or G2 to 
mitosis transition).90 Although there are at least sixteen types of cyclins, only cyclins A, 
B, D, E, and H are seen in cell cycle activity.90 Notably, cyclin D is active during G1, 
cyclin E promotes the G1 to S transition and is active during S phase (along with cyclin 
A), and cyclin B regulates early M phase events.93,94 Phosphorylation is also a major 
regulator for CDKs, with activating and inhibitory phosphorylation events. When the 
phosphatase Cdc25 dephosphorylates CDK at an inhibitory site, the CDK becomes 




by the active kinases Wee1 or Myt1, results loss of CDK activity and thus cell cycle 
arrest.90,91,95–101 
 In order to regulate and maintain proper cell cycle progression, cell cycle 
checkpoints are present to ensure DNA is properly replicating and to prevent damaged 
cells from progressing through the cell cycle.91,97,102 During these checkpoints, if the cell 
detects DNA damage or issues with DNA replication, it will induce cell cycle arrest to 
allow time to repair or to prepare for programmed cell death (apoptosis).95–97,100,103 Cell 
cycle arrest can be initiated by the activation of tumor suppressor proteins such as p53 or 
by CDK inhibitors such as p21.90,95,99 In the presence of DNA damage, a cascade of 
events involving the DNA damage response (DDR) signaling pathway is activated to 
activate ataxia‐telangiectasia‐mutated (ATM) and ataxia‐telangiectasia‐mutated and rad3 
related (ATR) protein kinases.100,104–107 Activation of ATM and ATR result in 
phosphorylation of either p53 or p21 or of Chk1 or Chk2 (checkpoint control proteins). 
Phosphorylation of p53 and p21 results in cell cycle arrest at the G1/S 
transition.90,91,96,100,104,107 Phosphorylation of Chk1 via ATR results in phosphorylation 
(deactivation) of Cdc25C and subsequent phosphorylation/deactivation of CDK1 (thus a 
G2/M transition cell cycle arrest), while phosphorylation of Chk2 via ATM results in 
phosphorylation (deactivation) of Cdc25A which in turn phosphorylates/deactivates 
CDK2 (thus a G1/S transition cell cycle arrest).90,91,93,96,100,104,107–109 
 Cancer is the result of uncontrolled cell proliferation.90 Exogenous factors can 
alter regular cell cycle function or can cause mutations to proto-oncogenes or tumor 




proliferation, while mutated tumor suppressor genes will not stop cell cycle progression 
when needed.99,102,110 Cycle dysregulation can also involve mutations or issues with 
CDKs, cyclins, other CDK substrates, as well as other cell cycle checkpoint proteins like 
Chk1 and Chk2.99,100,111 
 This dissertation project described the investigation of the effects of chlorpyrifos 
and its active metabolite chlorpyrifos-oxon on EBV-host/cell interactions in B-
lymphocyte cells, with specific focus on EBV and B-lymphocyte replication. Our initial 
conceptual model for our hypothesis was that CPF and CPO irreversibly binds to B-
lymphocyte AChE to inhibit the breakdown of acetylcholine and therefore accumulation 
of acetylcholine outside of the cell and depletion inside the cell (Fig. 3A). We also 
hypothesized that the presence of chlorpyrifos would affect both EBV and B-lymphocyte 
replication by organophosphate induced cytotoxicity. Additionally, we hypothesized that 
the presence of Epstein-Barr virus and the pesticide chlorpyrifos (and the active 
metabolite chlorpyrifos-oxon) would interact and initiate a combined effect on three 
different B-lymphocyte cell lines, two with the virus and one without the virus. That is, 
we thought cells infected with the virus would have a greater and different response in 
comparison to the cells without the virus (Fig. 3B). However, after analysis of our results, 
we now believe the interaction between the host cell and the presence of EBV and 
chlorpyrifos was more so a potentiation relationship/effect. With a potentiation effect, we 
saw that presence of EBV showed a protective response when cells were under 
organophosphate influenced stressors in comparison to EBV-negative cells. This effect 




responses are delayed when cells were exposed to high concentrations of the 
organophosphate. In contrast, this effect could be a potentially dangerous disadvantage 
for host cells and human health given the same delayed in cellular response (e.g. cell 
cycle arrest at higher concentrations of CPF or CPO).  
The results from this basic research approach will provide further insight about 
environmental virus-host interactions at the cellular level and how these effects can alter 
important cellular signaling pathways and mechanisms which in turn can impact human 
health. Overall, we found it fascinating that the presence or absence of EBV made a 
difference in how cellular mechanisms and pathways in B-lymphocytes reacted in the 














Figure 3. Initial Conceptual Models for the Effects of EBV Infection and 
Organophosphate Exposure. (A) Presence of organophosphates may cause 
acetylcholine buildup on the outside of B-lymphocyte cells and thus cause cellular 
damage and problems with cellular regulation. (B) Both EBV and organophosphates 
can cause independent health concerns, but the combination of both may cause a 
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ORGANOPHOSPHATE EXPOSURE CAUSES VIRAL AND CELLULAR 
DYSREGULATION IN B-LYMPHOCYTE CELLS 
 




Epstein-Barr virus (EBV) is one of the most prevalent human herpesviruses, 
infecting more than 90% of the adult population.1 The virus is known to be associated 
with a variety of human health issues including infectious mononucleosis, Burkitt’s 
lymphoma, Hodgkin’s and non-Hodgkin’s lymphoma, and nasopharyngeal carcinoma 
and cancer.1 Although EBV is a well- studied, ubiquitous virus, there is still a knowledge 
gap in virus-environmental interactions in relation to human health. An example of an 
understudied virus-environmental interaction is the potential relationship between EBV, 
pesticides, and cancer formation.  
Organophosphate pesticides are commonly used worldwide, both in an 
agricultural and residential context (though most organophosphates have been banned, 
phased out, or restricted for residential use in the U.S. starting by the year 2006).3,4,11  
According to the Environmental Protection Agency (EPA), some organophosphates are 
moderately toxic and non-carcinogenic.3,4 Organophosphates act as neurotoxins, targeting 




prevents the breakdown of acetylcholine to choline and acetate, and thus leads to 
acetylcholine accumulation, hyperstimulation of acetylcholine receptors, and eventual 
neurotoxicity.5 Organophosphates, in particular chlorpyrifos (CPF), have mainly been of 
concern for young children due to the pesticide’s ability to cause developmental 
issues.112–115 Recently, it has been suggested that the EPA ban CPF for agricultural use 
because of these developmental problems. Other studies have investigated how 
organohalogens, organochlorines, and organophosphates are toxic or contribute to 
developmental issues in environmental ecosystems like fresh water aquatic systems (from 
agriculture runoff) and animals (including farm livestock, birds, fishes, and 
amphibians).75,116,117  Other commonly used pesticides like organohalogens and 
organochlorines have been previously studied in relation to antibody titers of EBV 
antigens and risk of non-Hodgkin’s lymphoma. These studies concluded that blood 
samples with increased titer levels of EBV early antigen IgG have increased risk for hairy 
cell leukemia and other forms of non-Hodgkin’s lymphoma with the presence of 
organochlorines and organohalogens.118–120 Here, we are interested in how pesticides 
affect ubiquitous viruses like EBV and how the pesticide-virus interactions can contribute 
to human health at the cellular and molecular level.  
Although some moderately-toxic organophosphate pesticides are considered non-
carcinogenic, there have been several international meta-analyses that have investigated 
the relationship between lymphomas (Hodgkin and non-Hodgkin) and occupational 
exposure to pesticides. Many of these case studies focus around individuals who closely 




their families.6,8,14–16,121–124 Some studies analyzed data relating to individuals who have 
lymphomas and compared them to occupational exposure to a variety of different 
pesticides including organophosphates,6,7 while other studies collected urine samples 
13,124,125 or blood samples and looked for residual waste products of the 
organophosphates.126 These studies found mixed results from their analyses for linking 
pesticide exposure and lymphoma formation; studies either cited a weak122 or moderate 
correlation and stated that further studies needed to be conducted to factor in other 
variables.6,8,123 With such inconclusive results, it is critical to investigate, outside of case 
study data, how two environmental factors, both potentially linked to cancer and other 
adverse health issues, interact with each other and contribute to human disease.  
Here we examine how both the virus and host cells are affected when EBV 
infected B cells are exposed to organophosphate pesticides chlorpyrifos (CPF) and its 
active metabolite chlorpyrifos-oxon (CPO). Specifically, we investigated essential 
cellular mechanisms, including cell viability and the cell cycle, to determine if and how 
basic cellular biology was altered in the presence of an organophosphate, comparing 
EBV-positive (EBV+) and EBV-negative cells (EBV-). We used concentrations of CPF 
and CPO that represent the high end of environmental exposure (100-125 µM) as well as 
concentrations that exceed those environmental levels (150-200 µM).127 As EBV requires 
host cellular machinery/mechanisms to be maintained in cells and to propagate, we also 
investigated how EBV biology itself was altered at the protein level, when EBV+ cells 




Only one other similar study has been undertaken to our knowledge. A study by 
Zhou et al. presented evidence that CPF caused oxidative stress in Raji cells [EBV+, 
Burkitt’s lymphoma (BL)]. This was the only cell line used in their study and they report 
that CPF exposure caused latent EBV to reactivate when cells were exposed to CPF.128 
Within our study however we were not able to reproduce reactivation of EBV in EBV+, 
BL cells or other EBV lymphoblastoid cell lines upon any CPF exposure.   
Here, we postulate that the organophosphate, CPF and CPO (active metabolite) 
bind to acetylcholine receptors on B cells and thus also irreversibly bind to AChE. The 
CPF and CPO presence and binding to AChE would then result in the accumulation of 
acetylcholine outside the cell, and thus prevent sufficient amounts of choline, and acetate 
inside the cell for B cell function and survival (Fig. 4A). We hypothesize that the 
combination of EBV infection and organophosphate exposure results in a synergistic 
effect that affects human health at the cellular level (Fig. 4B).  
Our investigation of how organophosphates affected EBV+ and EBV- cells 
showed that cell viability decreased as the concentration of CPF, but not CPO, increased 
[EBV+, non-BL and EBV-, BL]. Additionally, we observed that both CPF and CPO 
induced a G1/S transition cell cycle arrest in EBV+ and EBV- cells. We also concluded 
that proteins necessary for EBV replication and proteins known to regulate EBV 
replication were affected with CPF and CPO exposure. Most interestingly though, we 
found that in almost all of our results, EBV- cells were overall more sensitive to the 
organophosphate exposure and elicited responses at lower concentrations in comparison 




That is, EBV- cells responded appropriately with CPF and CPO activity, while EBV+ 















Figure 4. Initial Conceptual Models for the Effects of EBV Infection and 
Organophosphate Exposure. (A) Presence of organophosphates may cause 
acetylcholine buildup on the outside of B-lymphocyte cells and thus cause cellular 
damage and problems with cellular regulation. (B) Both EBV and organophosphates 
can cause independent health concerns, but the combination of both may cause a 




2. Materials and Methods 
2.1. Cell Culture 
IM9 and Raji are immortalized, human derived B-lymphocyte cell lines that are 
infected with EBV. IM9 cells are non-cancerous, derived from an individual with 
infectious mononucleosis [EBV+, non-Burkitt’s lymphoma (BL)] (ATCC), while Raji 
cells are cancerous, derived from an individual with Burkitt’s lymphoma (EBV+, BL) 
(ATCC). Ramos cells are a B-lymphocyte cell line derived from an individual with 
Burkitt’s lymphoma, but not infected with EBV (EBV-, BL) (ATCC). Cells were 
maintained at 37ºC and 5% CO2 with RPMI-1640 media containing 10% fetal bovine 
serum, plus penicillin, streptomycin, and fungicide.  
2.2. Organophosphate Pesticides  
Organophosphates used in this experiment include CPF and CPO (the active 
metabolite). CPF and CPO (Chem Service Inc., West Chester, PA) were dissolved in 
DMSO for a final stock concentration of 100 mM.  
2.3. Treatment Conditions 
Cells were either left untreated, were treated with vehicle (DMSO, Sigma 
Aldrich), or were treated with organophosphate (ranging from 0-300 µM). Treatments 
were incubated for 24 hr prior to assays. EBV+ cells were induced into the lytic cycle 







2.4. Cell Viability 
Cell viability was assayed with the Guava ViaCount reagent (Millipore Sigma, 
USA) according to manufacturer’s protocol. Prepared samples were analyzed using the 
Guava easyCyte flow cytometer and the ViaCount program. Cell count was also carried 
out by the ViaCount program.  
2.5. Cell Cycle 
Cell cycle stages were determined with Guava Cell Cycle reagent (Millipore 
Sigma, USA) according to manufacturer’s instructions. Samples were incubated in the 
dark at room temperature for 30 minutes prior to analysis using the Cell Cycle program 
on the Guava easyCyte flow cytometer.   
2.6. Western Blot  
Protein samples were lysed with ELB lysis buffer (0.25M NaCl, 0.1% NP4O, 50 
mM HEPES pH 7.5, 5 mM EDTA, and protease/phosphatase inhibitors) and 20-40 µg 
were run on a 10% SDS-PAGE gel at 200V and transferred to an Immobilon membrane 
(Millipore) overnight at 100 mA.  
2.7. Immunoblotting 
Blots were blocked with 0.25% milk block solution (0.25% milk, 1x PBS, and 
0.1% Tween-20). Primary antibodies used include α Tubulin (1:500; Santa Cruz 
Biotechnology), 𝛽-Actin (C4) (1:500; Santa Cruz Biotechnology), EBV ZEBRA (BZ1) 
(1:500; Santa Cruz Biotechnology), and EBV EBNA-1 (1EB12) (1:500; Santa Cruz 
Biotechnology) overnight at 4ºC. Secondary antibodies used include goat-anti-mouse IgG 




Inc) for 10 minutes at room temperature. After each primary and secondary antibody 
incubation, blots were washed four times with Western wash solution (1x PBS, 0.1% 
Tween-20) using the SNAP i.d. 2.0 Protein Detection System (Millipore). Imaging and 
quantification were done using the C-DiGit Western Blot Scanner (LiCOR).  
2.8. Statistical Analysis  
A two-tailed student T-test was used to establish statistical significance with p-
values <0.05 as significant for Western blots. A one-way ANOVA with a Dunnett’s 
multiple comparison test was used for analysis when comparing treatments to the control 
when the standard deviations were equal while a Dunnett’s T3 multiple comparison’s test 
was used for unequal variance (with a Welch’s one-way ANOVA). Statistical analysis 
and graphs were made using PRISM’s Graphpad using the mean of all the trials and 
SEM.  
3. Results 
3.1 Chlorpyrifos, but not Chlorpyrifos-Oxon, Exposure Negatively Affects Cell Viability 
of B-Lymphocyte Cells  
To determine if chlorpyrifos (CPF) treatment was toxic to cells, EBV+, BL and 
EBV+, non-BL cells were exposed to 14 different concentrations (10, 20, 40, 50, 70, 80, 
100, 125, 150, 175, 200, 250, 275, and 300 µM) of CPF or to the DMSO vehicle for 24 hr 
and were assessed for cell viability (Fig. 5). EBV+, BL cell viability was statistically 
unaffected by CPF treatments relative to the DMSO control (93% viable). Treatments 
that ranged from 10-125 µM were 88%-94% viable. From 150 µM to 300 µM, there was 




down to 49% viable) (Fig. 5A). EBV+, non-BL cell viability was more greatly affected 
by the CPF exposure with three of the treatment doses (175, 275, and 300 µM) and 
showed decreased cell viability with statistical significance in comparison to the DMSO 
control (91%viable) (Fig 4B). EBV-, BL cells were exposed to 100, 125, 150, 175, and 
200 µM CPF, and showed statistically significant decreased viability at 125 and 175 µM 
in comparison to the DMSO control (Fig. 5C). Notably, the EBV+, BL and EBV+, non-
BL cells remained viable at concentrations of CPF that were toxic to the EBV- cell line 
(125 µM).  
Concentrations of the active metabolite of CPF, chlorpyrifos-oxon (CPO) used in 
subsequent experiments were based on results from this cell viability assay using CPF 
(Table 2). CPO was also tested for its effects upon cell viability on all three cell lines. 
Interestingly, this compound caused no statistically significant changes in cell viability 
(Fig. 5).  
To investigate why CPF caused changes in cell viability and not CPO, we also 
looked at overall cell concentration (cells/mL) for each cell line and treatment (Fig. 6). 
CPF treated cells showed decreased total number of cells with increased CPF 
concentration, a similar trend to CPF cell viability results (Fig. 6A-C). CPO treated cells 
however showed that EBV+, BL cells increased in cell concentration in comparison to 
the DMSO control, EBV+, non-BL cells varied, but overall had a trend of slightly 
decreased cell concentrations, and EBV-, BL cells showed dramatic decrease of cell 




Overall these results showed that EBV-, BL cells were more sensitive in assessing 
CPF exposure and cell viability. The results also showed that CPF affected B-lymphocyte 
cell viability more than CPO. Our results that looked at cell concentration provided 
evidence that CPF affects cell proliferation in a concentration dependent manner for all 
three cell lines. CPO treated cells showed that cell proliferation was not affected in 
EBV+, BL, but only slightly decreased cell viability in EBV+, non-BL, however; EBV-, 





Organophosphate Concentration Used (µM) 
Chlorpyrifos 10, 50, 100, and 300 
Chlorpyrifos-oxon 100, 125,150, 175, and 200 



























Figure 5. CPF Decreased Cell Viability while CPO showed no Change in Cell 
Viability in B Cells. (A) EBV+, BL, (B) EBV+, non-BL were treated with CPF (0-300 
µM) for 24 hours, while (C) EBV-, BL were treated 0-200 µM of CPF. To compare to 
the parent compound, (D) EBV+, BL, (E) EBV+, non-BL, and (F) EBV-, BL cells 
were exposed to CPO for 24 hours at 100, 125,150, 175, and 200 µM. ViaCount 
reagent (EMDMillipore) and flow cytometry was used to measure cell viability of host 
cells when exposed to the insecticide. * indicates p-value <0.05, CPF=Chlorpyrifos, 
CPO=Chlorpyrifos-oxon, n= 4 for EBV+, BL for CPF treatments, n=5 for EBV+, non-
























Figure 6. Increasing Concentrations of CPF Decreased Total Cell Concentration while 
Increasing Concentrations of CPO Affected Total Cell Concentrations in EBV- Cells. 
(A) EBV+, BL, (B) EBV+, non-BL, and (C) EBV-, BL cell lines were exposed to CPF 
for 24 hours. While (D) EBV+, BL, (E) EBV+, non-BL, and (F) EBV-, BL cell lines 
were exposed to CPO for 24 hours. Cells were analyzed via flow cytometry to 
determine the total cell concentration of each sample. * indicate p-values < 0.05 when 




3.2 Organophosphates Alter Cell Cycle Regulation of B Cells 
To determine if CPF exposure could affect cell cycle progression from one phase 
to another (G1, S, G2, and back into G1), EBV+, BL, EBV+, non-BL, and EBV-, BL 
cells were treated with four different concentrations of CPF (10, 50, 100, and 300 µM) or 
the DMSO vehicle for 24 hr and were assayed for cell cycle phases (G1, S, or G2) (Fig. 
7). All cell lines exposed to CPF at all treatment doses did not show statistically 
significant changes in the percentage of cells in G1 phase (Fig. 7). EBV+, BL cells had a 
statistically significant decrease of the percentage of cells in S phase at 300 µM (9.95%) 
in comparison to the DMSO control (18.78%) (Fig. 7A). EBV+, non-BL and EBV-
negative, BL cells did not have any statistically significant changes in the percentage of 
cells in S phase (Fig. 7B and 7C). All three cell lines showed decreased percentage of 
cells in G2 phase with statistical significance in comparison to the DMSO control (Fig.7): 
EBV-+, BL (DMSO: 17.18%, 300 µM: 8.25%), EBV+, non-BL (DMSO: 25.65%, 300 


























Figure 7. High Concentrations of CPF Induced Cell Cycle Arrest in B Cells. (A) 
EBV+, BL, (B) EBV+, non-BL, and (C) EBV-, BL cell lines were exposed to CPF for 
24 hours. Cells were analyzed via flow cytometry to determine the percentage of cells 
in G1, S, or G2 phase of the cell cycle. * indicate p-values < 0.05 when compared to 




Since the active metabolite is typically more toxic than the parent compound, we 
wanted to see if the potentially more toxic metabolite would cause cell cycle arrest at 
lower concentrations. We exposed CPO to all three cell lines at five different 
concentrations (100, 125, 150, 175, and 200 µM). In EBV+, BL cells exposed to the 
CPO, the average percentage of cells in G1 phase increased with concentration in 
comparison to the DMSO control (42.6%): 100 µM (48.96%), 125 µM (53.4%), 150 µM 
(56.33%), 175 µM (58.53%), and 200 µM (56.26%) (Fig 8A). The mean percentage of 
exposed cells in S phase of the cell cycle overall decreased with increased concentrations 
of the CPO when compared to the DMSO control (13.8%): 100 µM (15.86%), 125 µM 
(11.5%), 150 µM (9.6%), 175 µM (7.63%) and 200 µM (7.43%), with statistical 
significance at 175 and 200 µM (Fig. 8A). The average percentage of cells in G2 phase 
also decreased with increased concentrations compared to the control (22.53%): 100 µM 
(13.8%), 125 µM (13.43%), 150 µM (13.8%), 175 µM (14.6%) and 200 µM (17%), with 
statistical significance at 125 µM (Fig. 8A). For EBV+, non-BL cells, the mean 
percentage of cells in G1 phase in comparison to the DMSO control (14.28%) were as 
follows: 100 µM (22.05%), 125 µM (24.38%), 150 µM (28.20%), 175 µM (26.43%), and 
200 µM (25%) (Fig. 8B). The average percentage of EBV+, non-BL cells in S phase in 
comparison to the control (5.62%) were as follows: 100 µM (5.1%), 125 µM (6.55%), 
150 µM (9.35%), 175 µM (8.72%), and 200 µM (10.95%), with statistical significance at 
150 µM and 200 µM (Fig. 8B). The mean percentage of EBV+, non-BL cells in G2 phase 
initially increased at 100 µM (40.05%), 125 µM (38.90%), and 150 µM (34.90%) and 




control (32.30%) (Fig.8B). The average percentage of EBV-, BL cells at G1 phase 
increased at all concentrations compared to the control (23.43%): 100 µM (29.63%), 125 
µM (31.73%), 150 µM (32.63%), 175 µM (34.70%), and 200 µM (36.17%) with 
statistical significance at 100 µM, 175 µM, and 200 µM (Fig. 8C). The percentage of 
cells in S phase did not show any statistical significance throughout treatments in 
comparison to the DMSO control (19.20%): 100 µM (18.97%), 125 µM (20.13%), 150 
µM (19.67%), 175 µM (16.63%), and 200 µM (18.23%) (Fig. 8C). Similarly, the average 
percentage of EBV-, BL cells in G2 phase did not show any statistically significant 
differences when treatments were compared to the DMSO control (23.63%): 100 µM 
(21.83%), 125 µM (21.07%), 150 µM (20.53%), 175 µM (19.90 %), and 200 µM (16.90 
%) (Fig. 8C).  
Taken together, these data indicated that the parent compound induced cell cycle 
arrest at the G1/S transition at high concentrations (300 µM). Whereas the oxon form, 
CPO, had the ability to cause cell cycle arrest at the G1/S transition in EBV- cells at 
lower concentrations (starting at 100 µM) in comparison to EBV+ cells. Interestingly, 
there was increased entry into S phase within EBV+, non-BL cells that were not yet 
cancerous, at specific doses (150 µM and 200 µM). This suggested that the active 
metabolite of CPF can potentiate with EBV to promote cell cycle progression under 
conditions that would normally halt the cell cycle and/or kill the exposed cells. Overall 
these results showed, again, that EBV-, BL cells were more sensitive and induced proper 
cellular response (cell cycle arrest in the presence of cytotoxic stressors) at lower 




















Figure 8. CPO Exposure Induced Cell Cycle Arrest to B Cells in a Dose Dependent 
Manner. (A) EBV+, BL, (B) EBV+, non-BL, and (C) EBV-, BL cell lines were 
exposed to CPO for 24 hours. Cells were analyzed via flow cytometry to determine 
the percentage of cells in G1, S, or G2 phase of the cell cycle. * indicate p-values < 
0.05 when compared to the vehicle control group (DMSO). EBV+, BL and EBV-, BL: 




3.3 Chlorpyrifos-Oxon Exposure Alters Expression of Important Viral and Cellular 
Proteins 
To understand viral changes that may be occurring in EBV+ cells at a dose of 
organophosphate that did not cause major effects, cells were exposed (for 24 hours) to 
100 µM of CPF or CPO in the presence of TPA/NaB, a chemical inducer of the EBV 
lytic life cycle. The 100 µM concentration of CPF or CPO was chosen since both EBV+ 
cell lines showed decreased cell viability, without killing cells when exposed to CPF 
during preliminary analysis; the same concentration was used for CPO since the active 
metabolite is typically more toxic than the parent compound. BZLF1 is an important 
EBV protein that acts as a transactivator for EBV early genes (necessary for viral 
replication). EBV+, BL cells showed decreased expression of the viral protein BZLF1 
when compared to cells only exposed to TPA/NaB: the effect of the oxon form was the 
most dramatic (Fig. 9A). We found neither CPF nor CPO were able to induce lytic 
replication on their own, however (Fig. 9A). These results refute the results by Zhao et al, 
who claimed that CPF treatment of EBV+, BL cells readily triggered lytic replication128.  
Under the same conditions, EBV+, non-BL cells showed increased expression of 
BZLF1 when exposed to CPF, but showed decreased expression of BZLF1 when cells 
were exposed to CPO (Fig. 9B). Similarly, neither CPF nor CPO alone were able to 
induce lytic replication without TPA/NaB treatment.  
 EBV+, BL and EBV+, non-BL cells were exposed to a dosage series of CPO and 
Western blots were probed for the EBV latent protein EBNA1. EBNA1 is important for 




EBV+, BL cells did not show any expression changes of EBNA1 (Fig. 10A). While 
EBV+, non-BL cells, however, showed EBNA1 expression increased with statistical 
significance as compared to the DMSO control at 125 µM and 175 µM (Fig. 10B).  
Overall, these results indicate that a dose of CPO that caused no visible cellular 
effects (in terms of cell viability and cell cycle) was able to have dramatic effects upon 
EBV gene expression. Such changes to viral gene expression may be the underlying 





















Figure 9. CPF and CPO Exposure Altered EBV BZLF1 Expression. (A)EBV+, BL 
cells treated with 100 µM CPF or CPO when the virus was active showed decreased 
expression in the viral protein BZLF1. (B) EBV+, non-BL cells treated with 100 µM 
CPF showed increased expression of BZLF1, while CPO showed decreased 
expression of BZLF1 when the virus was active. Induction of lytic replication was 
through chemical induction using TPA/NaB. Cells were treated with CPF or CPO and 
chemically induced for 24 hours. TPA/NaB= 12-O-Tetradecanoylphorbol-13-acetate 
and sodium butyrate, CPF= chlorpyrifos and CPO = chlorpyrifos-oxon. n=3, * indicate 













Figure 10. CPO Exposure Increased Expression of Latent EBV Protein EBNA1 in 
EBV+, non-BL Cells, but not EBV+, BL Cells. (A) EBV+, BL cells and (B) EBV+, 
non-BL (B) were treated with CPO for 24 hours. EBNA1 was standardized to the 
loading control (α-Tubulin) and treatments were compared to the DMSO control. 




As viral protein levels were altered under CPO treatment conditions, we wanted 
to examine how CPO affected cellular protein levels, especially proteins that are also 
associated with and regulate EBV replication. One important regulator of protein 
translation is p70S6K, a kinase that is phosphorylated by mTORC1. Phospho-p70S6K in 
turn phosphorylates a variety of targets, most notably the ribosomal subunit S6; such 
activation is essential for protein translation.129 EBV+, BL, EBV+, non-BL, and EBV-, 
BL cells were exposed to increasing doses of CPO (100, 125, 150, 175, and 200 µM) and 
Western blots were probed for phosphorylated p70S6K. EBV+, BL cells showed no 
changes in phosopho-p70S6K levels until the 200 µM dose, which exhibited a 
statistically significant decrease (Fig.11A). In contrast, EBV+, non-BL cells showed a 
statistically significant decrease of phospho-p70S6K at the lowest concentration of CPO 
(100 µM), but as the CPO dose increased, so did the phospho-p70S6K levels (Fig. 11B). 
EBV-, BL cells showed no change of phospho-p70S6K levels until the 200 µM dose, 
which exhibited a statistically significant increase (Fig. 11C). We did not probe for total 
p70S6K in this study. Interestingly, these results showed that EBV+ cells decreased in 
phosphorylated p-70S6K while EBV- cells increased in phosphorylated p-70S6K. These 
results also provided further evidence that presence of EBV alters how B-lymphocytes 
function. We were also curious to investigate if latency regulation was affected by CPO 
exposure so we investigated the cellular protein Ying-Yang1 (YY1). 
YY1 is an essential, ubiquitous transcriptional activator and repressor that acts 
through DNA promotor tethering.130,131 This is an important protein to investigate as it 




apoptosis) and response to genotoxic stimuli,55 as well as viral regulation of EBV latency 
(driving the virus to remain latent).55,130,132 EBV+, BL, EBV+, non-BL, and EBV-, BL 
cells exposed to CPO (100, 125, 150, 175, and 200 µM) for 24 hours were probed for the 
cellular protein YY1. EBV+, BL cells did not show any YY1 expression changes (Fig. 
12A). EBV+, non-BL cells only showed decreased YY1 expression with statistical 
significance at 200 µM (Fig. 12B). In contrast, EBV-, BL cells showed a statistically 
significant increase of YY1 expression at 125 µM of CPO (Fig. 12C). Overall, though, 
YY1 expression did not change drastically with increasing concentration of CPO, 
regardless of cell line. Presence and expression of YY1 would indicate a drive to keep the 
EBV latent replication.  
For the two cellular proteins we assessed, we found that phospho-p70S6K showed 
a general trend for decreased levels within both EBV+ cell lines, while increased 
expression in the EBV- cell line. This correlated with our findings that CPO decreased 
EBV BZLF1 expression; we know from previous work that EBV lytic replication and 
BZLF1 levels were dependent upon mTORC1 activity, and specifically phospho-p70S6K 
levels (unpublished). This indicated that CPO exposure may cause mTOR pathway 
inhibition in an EBV specific manner. We also found that YY1 levels did not change in 
EBV+, BL cells, but decreased in EBV+, non-BL cells at the highest dose, and increased 
in EBV-negative, BL cells at lower doses. This indicated that YY1 not only appears to be 
unaffected by CPO exposure, but also may have influenced lytic EBV to shift to latency 












Figure 11. CPO Exposure Decreased Expression of p-p70S6K in EBV-Positive Cells, 
but Not EBV-Negative Cells. (A) EBV+, BL, (B) EBV+, non-BL, and (C) EBV-, BL 
cells were treated with CPO for 24 hours and assessed for the expression of 
phosphorylated p70S6K via Western Blot. Treatments were compared to the DMSO 















Figure 12. YY1 Expression in B Cells was not Greatly Affected by CPO Exposure. 
(A) EBV+, BL, (B) EBV+, non-BL, and (C) EBV-, BL cells were treated with CPO 
for 24 hours and assessed for YY1 expression via Western Blot. Treatments were 
compared to the DMSO control and standardized to a loading control (actin or 




4. Discussion and Conclusion 
Studying virus-host interactions is important to discover crucial details about 
cellular and viral responses and how they affect diseases related to viral infection. The 
relationship between virus-host interactions and how they are affected by exogenous 
environmental factors, such as pesticides, remains unclear. This study investigated 
whether the presence of EBV infection and organophosphate pesticides (CPF and its 
active metabolite CPO) created a potentiated effect that would cause changes to the virus 
and to host cells, thus contributing to a disease (such as cancer) phenotype more so than 
either factor alone. We found that a globally used insecticide, CPF, and its active 
metabolite CPO, affected B-lymphocyte cell viability, cell proliferation,  cell cycle 
progression, and EBV protein expression. 
In terms of cell viability, EBV- cells were most sensitive to CPF at lower doses, 
whereas EBV+ cells experienced little to no change in cell viability at these lower doses. 
EBV+, non-BL cells were the most sensitive to CPF at higher doses. Interestingly, CPO 
exposure at all doses had little effect on both EBV+ and EBV- cells. In fact, EBV+, BL 
cell line experienced higher cell viability percentages (though not statistically significant) 
in comparison to the EBV-, BL cell line. With cell proliferation (cell concentration, 
cells/mL), we saw that with CPF exposure, both EBV+ and EBV- cell lines experienced 
decreased cell concentrations with increasing concentrations of CPF. However, with CPO 
exposure, EBV+ cell lines overall did not show any decreased cell concentrations 
whereas EBV- cells showed a drastic decrease in cell concentration. The differences of 




different molecular target to cause cell death more readily in comparison to cells exposed 
to CPO. These results provided us with 1) a series of pesticide doses to use in subsequent 
experiments that were not just toxic to cells, and 2) the knowledge of other cellular 
changes (for example, changes to the cell cycle stages) would not be artifacts of toxicity. 
Together, we saw that presence of EBV made the cells more resistant or protected when 
exposed to the organophosphate.  
For the cell cycle, we found that CPF exposure likely induced a G1/S transition 
cell cycle arrest at high concentrations (300 µM). The active metabolite, however, told a 
different story. CPO at the lowest dose (100 µM) was capable of eliciting a significant 
shift of cells into G1 phase in EBV-, BL cells, an expected response for cells exposed to a 
potentially damaging agent. EBV+ cells did not experience a significant shift of cells into 
G1, however, overall EBV+, BL and EBV+, non-BL both followed the trend of a G1/S 
transition arrest. These results suggest that the presence of the virus in these cells allowed 
for the continuation of DNA replication and mitosis despite exposure to a potentially 
damaging agent. If cytotoxic damage was occurring in these cells, it would likely be 
propagated. Again, it is interesting to note that EBV-, BL cells were once again more 
sensitive to CPO and triggered cell cycle arrest at lower concentrations.  
To examine the effects the organophosphate upon EBV biology, we monitored the 
expression of a lytic and latent EBV protein. We found that CPO caused decreased 
expression of the EBV protein BZLF1, an important transcription factor necessary for 
lytic viral replication. In contrast to a previous study by a different laboratory,128 we did 




organophosphate for 24 hours at 100 µM, nor 4 hours at 50, 100, 150, and 200µM (data 
not shown). The expression of EBNA1, an important protein for viral replication during 
latent EBV infection and for infected cell survival,1 was increased when EBV+ cells were 
exposed to CPO, specifically in EBV+, non-BL cells. The response we observed, that 
CPO decreased BZLF1 expression and increased EBNA1 expression, suggests that the 
pesticide drives cells towards a more latent state. Furthermore, increased EBNA1 levels 
have been recently positively correlated to an increased incidence of lymphoma.133 
Altogether, it appears that CPO causes EBV protein expression changes that both 
increase cell survival and promote cell cycle progression.  
P70S6K is downstream of the mTORC1 pathway within the PI3K/Akt signaling 
pathway and plays a major role in translation.134,135 When active, mTOR directly 
phosphorylates p70S6K, and this kinase then phosphorylates downstream targets to 
promote protein translation. Studies have shown that inhibitors of the mTOR pathway 
(such as rapamycin) directly affect phosphorylation of p70S6K expression.54,136,137 
Interestingly, when we examined phospho-p70S6K after 24 hours of CPO exposure, we 
noticed a trend of decreased levels of this protein in EBV+, BL (at 200 µM) and EBV+, 
non-BL cells (at 100 µM), while increased expression in EBV-, BL cells. As EBV 
utilizes the host mTOR pathway to translate its viral proteins during lytic replication, and 
actually promotes phosphorylation and activation of p70S6K (unpublished data), the fact 
that CPO led to decreased levels of phospho-p70S6K may at least partially explain why 
BZLF1 exhibited a decreased expression under CPO conditions. Results further provided 




YY1, another cellular protein that regulates EBV, is an essential protein that acts 
as both a transcriptional activator and repressor for both humans and viruses.130 For EBV, 
YY1 has been shown to act as a negative regulator for latent to lytic replication switches; 
YY1 represses BZLF1 transcription, leaving the virus to remain latent (inactive).130,132,138 
Our study showed that BZLF1 was not expressed in the absence of TPA/NaB and the 
presence of CPF or CPO. Consistent expression of YY1 throughout most of the 
treatments (with the exception of decreased expression of YY1 at 200 µM in (EBV+, 
non-BL cells) may have played a role as to why BZLF1 was not expressed in the absence 
of TPA/NaB and why EBNA1 did not deplete with increasing concentrations of CPO. It 
was likely that YY1 was unaltered during CPO exposure and continued to repress BZLF1 
production and keep EBV in the latent phase.  
Other studies have shown the cytotoxic and genotoxic effects of organophosphate 
exposure on different types of cells and tissues.139–141 These studies have also stated that 
the mechanisms and pathways involved with these effects are not fully understood. There 
are older studies that investigated pesticide exposure effects on EBV titers.118–120 
However, current literature have focused on other environmental factors, like 
environmental pollutants and lifestyle choices, and how it relates to EBV infection and 
associated diseases like nasopharyngeal carcinoma, gastric cancer, and multiple sclerosis. 
142–146  
We acknowledge that our study only investigated thoroughly one 
organophosphate and its active metabolite. Other organophosphates and combination 




interactions. The concentrations we chose for CPF and CPO exposure are relatively high 
in comparison to environmental exposure levels, however; the lower end of our range 
(100-125 µM) falls within reasonable and realistic environmental levels for humans.127  
Overall our study found that cells exposed to CPF and CPO exhibited a 
potentiated effect (as opposed to our initially hypothesized synergistic effect) depending 
if EBV was present or not. This effect appeared to have contributed to the survival and 
propagation of pesticide-exposed, EBV+ cells. EBV+ cells were only affected at higher 
doses of CPF or CPO, whereas, the EBV-, BL cells responded to CPF or CPO exposure 
more readily at lower concentrations. This protective or delayed cellular response when 
EBV+ cells are exposed to the organophosphate could potentially promote health issues, 
such as lymphoma formation, associated with EBV infection. Our revised model to 
explain EBV and pesticide relationship can be seen in Fig. 13.  
To further understand the effects of organophosphate exposure on viral and host 
replication, we need to understand the affected mechanisms or pathways from the 
presence of the pesticide. We suspect that DNA damage and oxidative stress may play a 
role in our results. We hypothesize that the organophosphate is binding to 
acetylcholinesterase receptors on B lymphocyte cells, creating irreversible inhibition 
when bound to AChE to then cause deficient levels of acetylcholine inside the cell. This 
deficiency may lead to DNA damage, oxidative stress, and other factors related to issues 
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EFFECTS OF OXIDATIVE STRESS AND DNA DAMAGE CONTRIBUTIONS TO 
ABNORMAL REGULATION IN EBV INFECTED B-LYMPHOCYTES 
 




Epstein-Barr virus (EBV) is one of the most common human herpesviruses, 
infecting more than 90% of adults worldwide. EBV is a known oncovirus associated with 
cancers like Burkitt’s lymphoma and other non-Hodgkin’s lymphomas, gastric cancer, 
and nasopharyngeal carcinoma.1 Several studies have investigated how EBV-associated 
diseases arise in the presence of environmental factors, for example, endemic Burkitt’s 
lymphoma and malaria, and nasopharyngeal carcinoma and lifestyle factors like smoking 
and diet.143,145,146,148 However, less commonly-studied areas are environmental virus-host 
interactions. For example, the effects moderately-toxic pesticides, like the 
organophosphate chlorpyrifos, have on the cellular mechanisms that EBV hijacks. One 
interesting and conceivable cellular pathway that the pesticide may be able to affect is 
oxidative stress and DNA-damage induced cell cycle arrest.  
When there is an imbalance between the production and capacity of antioxidants 
and the production of reactive oxygen species (ROS), like free radicals (hydroxyl and 




inability for cells to combat the free radical imbalance through antioxidant production or 
radical scavenging enzymes can lead to DNA, protein, and lipid damage.104,149–151 
Damage to macromolecules can therefore lead to major cellular issues like 
carcinogenesis, genotoxicity, and cytotoxicity. Oxidative stress is thus a factor that can 
contribute to the DNA damage response (DDR) and downstream consequences to cell 
cycle regulation, such as cell cycle checkpoints.104,151–153 In order to understand how 
chlorpyrifos can disturb the cell cycle, we first have to understand normal cell cycle 
function. 
In unperturbed cell cycle activity, unphosphorylated Cdc25s (Cdc25A and 
Cdc25C for example) have the responsibility of dephosphorylating cyclin dependent 
kinases (CDKs) via phosphatase activity.91 Removing the phosphate group from a CDK 
allows the cell cycle to progress.91 In the presence of ssDNA or stalled replication forks, 
ATR activates and in turn phosphorylates/activates Chk1at Ser317 and subsequently 
Ser345.91,96,106,154 Activated Chk1 can then phosphorylate Cdc25A or Cdc25C 
phosphatases.91,96,99,100,106 This phosphorylation of Cdc25A induces ubiquitin-mediated 
proteasome degradation of Ccd25A and thus inhibits activity/dephosphorylation of 
CDK1.91,96,97 Phosphorylation of Cdc25C by Chk1 causes inactivation and thus prevents 
dephosphorylation of CDK1, causing cell cycle arrest.91,96,97 Chk2 is activated through 
double stranded DNA breaks and subsequent ATM activation.95,155 Phosphorylated Chk2 
will similarly phosphorylate/inactivate Cdc25A or Cdc25C, but will inhibit CDK2 





while CDK2 inhibition results in G1 cell cycle arrest.100,108,155–158 A summarized diagram 
of normal cell cycle can be seen in Figure 14.  
Our previous study (Chapter 2) revealed that the moderately toxic insecticide 
chlorpyrifos (CPF) caused decreased cell viability for EBV+, non-BL cells and EBV-, BL 
cells, but not EBV+, BL cells. In contrast, its active metabolite chlorpyrifos-oxon (CPO) 
did not cause any changes in cell viability to any of the three cell lines used. We also 
observed overall cell concentrations were affected in a concentration dependent manner 
in all three cell lines for CPF. However, only EBV-, BL cells showed a noticeable cell 
concentration change when exposed to CPO (decrease total cell concentration with 
increasing CPO concentration). Our results also showed that CPF exposure at a high 
concentration (300 µM) led to likely G1/S transition cell cycle arrest for EBV+ and EBV- 
cells. Overall, CPO exposure at lower concentrations caused cell cycle arrest at the G1/S 
transition for EBV+ and EBV- cells. However, EBV-, BL cells were clearly more 
sensitive and were more readily entering cell cycle arrest at lower concentrations in 
comparison to EBV+, BL and EBV+, non-BL cells.  
To better understand our previous results and possible driving mechanisms of 
inducing cell cycle arrest, we decided to investigate oxidative stress, DNA damage, and 
the cell cycle checkpoints 1 and 2, in relation to CPO, CPF, and EBV interactions. Our 
results showed that CPO induced oxidative stress and affected EBV+ cells more so than 
EBV- cells. We also found that EBV+ and EBV- cells showed weak presence of DNA 
damage caused by either high doses of CPF and CPO. Interestingly, when we 




found that cell cycle checkpoint and DDR related proteins were still activated despite the 
overall low presence of DNA damage. EBV+ cells overall showed decreased levels of 
phosphorylated Chk1 (pChk1) at high doses and increased levels of phosphorylated Chk2 
(pChk2). Meanwhile, EBV- cells showed little change of pChk1 and pChk2 levels at all 
CPO exposure doses. Taken together with previous flow cytometry cell cycle data, it 
appears that CPO was able to induce cell cycle arrest at the G1/S transition in all cell 
lines. Results from this study also provided further evidence that the presence or absence 








Figure 14. Summary of Unperturbed Cell Cycle and DNA Damage Induced 
Cell Cycle Arrest. (A) Illustrates unperturbed cell cycle progression while 




2. Materials and Methods 
2.1 Cell Culture 
Two EBV+, B-lymphocyte, immortalized cell lines, Raji and IM9, and one EBV-, 
immortalized cell line, Ramos, were used in this study. Raji cells were derived from an 
individual who had EBV+ Burkitt’s lymphoma (EBV+, BL), IM9 cells were derived 
from an individual with EBV+ mononucleosis (EBV+, non-BL), and Ramos cells were 
derived from an individual with Burkitt’s lymphoma but without EBV infection (EBV-, 
BL). All cell lines were purchased from ATCC, and cultured at the following conditions: 
37ºC at 5% CO2, and maintained in RMPI-1640 medium with 10% fetal bovine serum, 
with streptomycin, penicillin, and fungicide. 
2.2 Organophosphate Pesticide 
This study mainly used the active metabolite of chlorpyrifos (CPF), chlorpyrifos-
oxon (CPO) (Chem Service Inc., West Chester, PA). CPF and CPO were prepped with 
DMSO for a stock solution at 100 mM and stored at -20 ºC.  
2.3 Organophosphate Treatments 
Cells were treated with DMSO for the vehicle control or at five concentrations 
(100, 125, 150, 175, 200 µM) of CPO for 24 hours. The TUNEL assay also included 200 
µM of CPF.  
2.4 General Oxidative Stress/CM-H2DCFDA 
To test general for general oxidative stress, the CM-H2DCFDA kit 
(Invitrogen/ThermoScientific) was used according to manufacturer’s protocol. This kit 




and peroxyl anions. Once the dye diffused into the cell, DCFDA underwent 
deacetylatation and oxidation by ROS to form 2,7-dichlorofluorescein or DCF. 
Therefore, if the organophosphate exposed to the cells generated oxidative stress, the 
ROS would oxidize the cells to produce DCF and make the samples fluoresce.  Samples 
were analyzed via Guava easyCyte flow cytometer (Millipore Sigma, USA) with InCyte 
software.  
2.5 DNA Damage/TUNEL Assay 
The presence of DNA damage was assayed using the APO-DIRECT™ kit (BD 
Biosciences) per manufacturer’s protocol using the Incyte software of the Guava 
easyCyte flow cytometer (Millipore Sigma, USA). EBV+, BL and EBV-, BL cells were 
tested with DMSO, 100, 150, 200 µM of CPO and 200 µM of CPF. Positive and negative 
control cells included in the kit were also used to establish presence or absence of DNA 
damage. After cells were treated and for 24 hours, cells were fixed in 1% 
paraformaldehyde (dissolved in 1x PBS) and stored in ice cold 70% ethanol before 
staining with FITC-dUTP (a fluorescent label) and propidium iodide. Presence of DNA 
breaks (both single stranded and double stranded breaks) at the 3’-OH termini were 
labeled with FITC-dUTP. Cells were also stained with propidium iodide to indicate intact 
DNA. Therefore, FITC-dTUP bound to DNA breaks fluoresced when assayed via flow 
cytometry.  
2.6 Western Blot and Immunoblotting  
Samples exposed to CPO at 100, 125, 175, and 200 µM were lysed with 0.25M 




inhibitors (ELB lysis buffer). Samples were stored at -80 ºC. 20-40 µg were 
electrophoresed on a 10% SDS-PAGE gel (at 200V) and transferred to an Immobilon 
membrane (Millipore) at 100 mA, overnight.  
After transferring proteins to the membrane, blots were blocked with 0.25% milk 
block solution (0.25% milk, 0.1% Tween-20, and 1x PBS). Primary antibodies and 
concentrations used to analyze proteins included: Total ATR (C1) (1:500, Santa Cruz 
Biotechnology), phospho-ATR (Thr68) (1:1000, Cell Signaling), phospho-
Chk1(Ser317)(D12H3)XP (1:1000; Cell Signaling), phospho-Chk2 (Thr68)(C13C1) 
(1:1000; Cell Signaling), total chk1 (1:500; Santa Cruz Biotechnology), 𝛽-Actin (C4) 
(1:500; Santa Cruz Biotechnology), and α Tubulin (1:500; Santa Cruz Biotechnology). 
Goat-anti-mouse IgG (H+L) and goat-anti-rabbit IgG (H+L) (Jackson ImmunoResearch 
Laboratories, Inc) were used as secondary antibodies at 1:5000 dilution for 10-20 minutes 
at room temperature. Blots were washed with wash solution (1x PBS, 0.1% Tween-20) 
four times after each primary and secondary antibody incubation. The SNAP i.d. 2.0 
Protein Detection System (Millipore) was used to perform the blot washes. 
WesternBright ECL (Advansta), a horseradish peroxidase (HRP) substrate, was used for 
chemiluminescent detection (incubated at room temperature for 5-10 minutes) before 
imaging and quantifying the blot on the C-DiGit Western Blot Scanner (LiCOR).  
Phosphorylated and total ATR and Chk1 levels were assessed separately via 
Western blot, but the phospho and total levels were also assessed by comparing the ratios 




to the loading control. The trials were then averaged and the ratio was calculated 
(phosphorylated levels/total levels).  
2.7 Statistical Analysis 
CM-H2DCFDA and immunoblotting were conducted with n=3 while the TUNEL 
assay was conducted with a sample size of n=4. CM-H2DCFDA and TUNEL assay used 
either a one-way ANOVA or a Welch’s one-way ANOVA and Dunnett’s multiple 
comparison or Dunnett’s T3 multiple comparison tests, depending on equal variances, to 
compare treatment groups to the DMSO control. Western blots were analyzed using a 
two-tailed, two-sample with unequal variance, student T-test to compare each treatment 
group to the DMSO control. Statistical significance was measured using p<0.05. Graphs 
represent both the average and individual data points from each trial. PRISM Graphpad 
was used for statistical analysis and to generate graphs. Only the averages of the 
Phospho/Total ratios for ATR and Chk1 protein levels were graphed. 
3. Results 
3.1 Chlorpyrifos-Oxon Induced Oxidative Stress in EBV-Positive B Cells but not EBV-
Negative B Cells 
Due to our previous work that indicated cell cycle dysregulation, presence of 
cytotoxicity at high concentrations, and altered expression of important regulatory 
proteins occurred in CPF and CPO treated B cells, (Chapter 2), it was of interest to 
investigate what factors contributed to these findings. EBV+, BL, EBV+, non-BL, and 
EBV-, BL cells were treated with CPO (100, 125, 150, 175, and 200 µM) for 24 hours 




reactive oxygen species (ROS) within cells. EBV+, BL cells exhibited an increased level 
of ROS at 100 µM (77.71%), 125 µM (78.33%), 150 µM (78.81%), 175 µM (85.83%), 
and 200 µM (87.34%) in comparison to the DMSO control (61.81%), with statistical 
significance at 175 and 200 µM (Fig. 15A). EBV+, non-BL cells showed no statistically 
significant increase of ROS when cells treated with CPO were compared to the DMSO 
control (67.37%): 100 µM (79.11%), 125 µM (83.13%), 150 µM (77.42%), 175 µM 
(82.96%), and 200 µM (83.53%), although there was a general trend of increased ROS 
presence with increased CPO dosage (Fig. 15B). EBV-, BL cells interestingly showed no 
statistical changes in ROS when treated samples were compared to the DMSO control 
(62.43%): 100 µM (66.80%), 125 µM (67.09%), 150 µM (65.41%), 175 µM (62.58%), 
and 200 µM (60.02%) (Fig. 15C).  
These results suggest that CPO exposure contributed to oxidative stress in EBV+ 
cells, but not in EBV- cells. This indicates that the presence of both EBV and the 
pesticide can interact to cause a greater level of cell damage versus the presence of 








3.2 EBV-Positive and Negative Cells Exhibited Low Levels of DNA Damage when 
Exposed to Chlorpyrifos-Oxon 
To further investigate factors that contributed to changes in B cell biology when 
exposed to CPF and CPO, we assayed for the presence of DNA damage with the TUNEL 
assay. This assay tests for the presence of damaged DNA associated with both ssDNA 
and dsDNA breaks. EBV+, BL and EBV-, BL cells were employed in this experiment 
and treated with 100, 150, or 200 µM of CPO or 200 µM of CPF. The percentage of 
FITC-dUTP that associated with DNA was measured in order to identify the presence of 
DNA damage in these cells. EBV+, BL cells did not show any statistically-significant 
differences in this assay when cells were treated with CPO or CPF when compared to the 
DMSO control (3.88%): CPO-100 µM (3.92%), 150 µM (4.55%), 200 µM (7.66%), and 
Figure 15. CPO Exposure caused Oxidative Stress in EBV-Positive Cells, but not 
EBV-Negative Cells. (A) EBV+, BL, (B) EBV+, non-BL, and (C) EBV-, BL cells 
were treated with CPO for 24 hours and assessed for the presence of oxidative stress. 




CPF 200 µM (8.32%) (Fig.16A). However, there was a general trend of increasing DNA 
damage with higher CPO or CPF doses (Fig.16A). EBV-, BL cells also showed a trend of 
increasing of FITC-dUTP incorporation with increasing concentrations when compared 
to the DMSO control (3.97%): CPO-100 µM (2.40%), 150 µM (7.98%), 200 µM 
(11.91%), and CPF 200 µM (24.21%), with statistical significance at 200 µM of CPF 
(Fig. 16B). These results suggest that CPO exposure triggers a minor amount of DNA 
damage in B cells.  Additionally, we saw that EBV-, BL cells appeared to be more 
sensitive to the increasing CPO concentrations and the CPF exposure when compared to 















3.3 CPO Exposure Caused Misexpression of Proteins Associated with the DNA Damage 
Response  
ATM and ATR (Ataxia-telangiectasia mutated/ATM-and Rad3-Related) are 
important kinases in the DDR pathway that phosphorylate specific proteins in the 
presence of DNA damage (ssDNA and dsDNA breaks). Activated ATR (and ATM) 
allow for phosphorylation and activation of cell cycle checkpoint proteins (such as Chk1 
and Chk2), which in turn initiate a cascade of phosphorylation events that lead to cell 
cycle arrest. An ATR response is activated in the presence of ssDNA and replication fork 
stalls, versus ATM’s activation through DNA double-stranded breaks.  
Figure 16. CPO Exposure Contributed DNA Damage to B Cells. (A) EBV+, BL 
and (B) EBV-, BL cells were treated with CPO or 200 µM CPF for 24 hours and 
assessed for the presence of DNA damage via the TUNEL assay. Treatments were 




We investigated, via Western blot, how CPO exposure affected phosphorylated 
and total ATR protein levels in EBV+, BL and EBV-, BL to further investigate if the 
presence or absence of EBV affected cellular function. EBV+, BL cells exposed to CPO 
showed a general decrease in phosphorylated ATR (phospho-ATR), with statistical 
significance at 175 µM (Fig. 17A). EBV-, BL cells showed a similar trend with a 
decrease in phospho-ATR levels, with statistical significance at 100, 125, and 150 µM of 
CPO when compared to the DMSO control (Fig. 17B). EBV+, BL cells showed a 
statistically-significant decrease of total ATR at 200 µM (Fig. 18). EBV-, BL cells did 
not show a statistically-significant decrease of total ATR, however there was a trend of 
decreased levels starting at 175 µM (Fig. 18). When comparing the phosphorylated levels 
to total levels, the EBV+, BL cell line showed a trend of decreased ratio with increasing 
concentrations of CPO, while the EBV-, BL cell line showed the inverse trend (Fig. 19). 
This suggested that CPO exposure caused a decrease in ATR production in EBV+, BL 
cells, whereas EBV-, BL cells appeared to have an initial decreased production of ATR 
then increased production with higher concentrations. Overall these results suggested that 
although still phosphorylated and active, ATR activity decreased in the presence of CPO. 
EBV-, BL cells particularly showed this decreased activity at lower concentrations in 












Figure 17. CPO Exposure Decreased Phosphorylated Levels of ATR in B Cells. Raji 
(A) EBV+, BL and (B) EBV-, BL cells were treated with CPO for 24 hours and 
assessed for the expression of phospho-ATR via Western Blot. Treatments were 













Figure 18. CPO Exposure Decreased Total Levels of ATR in B Cells. (A) EBV+, BL 
and (B) EBV-, BL cells were treated with CPO for 24 hours and assessed for the 
expression of total ATR via Western Blot. Treatments were compared to the DMSO 







Evaluation of cell cycle checkpoint activity was also of interest to us to 
understand if and how the DDR pathway played a role in CPO-exposed B cells. Chk1and 
Chk2 are not only are involved with cell cycle regulation, but also play roles in the 
regulation of DDR. We assed total and phosphorylated levels of Chk1 and Chk2 in 
EBV+, BL, EBV+, non-BL, and EBV-, BL cells when exposed to CPO via Western blot. 
Chk1 and Chk2 are activated (phosphorylated) by single-stranded DNA breaks/ATR 
activation, or double stranded DNA breaks/activation of ATM, respectively100,159–161. 
Compared to the DMSO control, EBV+, BL cells exposed to 175 µM and 200 µM of 
Figure 19. Phosphorylated ATR and Total ATR Ratios. (A) EBV+, BL and (B) EBV-, 
BL cells were treated with CPO for 24 hours. The phosphorylated and total levels of 




CPO showed statistically-significant decrease in phospho-Chk1 levels (Fig. 20A). This 
correlated with decreased levels of total Chk1 protein in EBV+, BL cells, with statistical 
significance at 175 µM (Fig. 21A). Similarly, EBV+, non-BL cells exposed to CPO at 
150 µM, 175 µM, and 200 µM showed statistically-significant decreases of phospho-
Chk1, compared to the DMSO control (Fig. 20B). This also correlated with the decreased 
levels of total Chk1, with statistical significance for all treatments when compared to the 
DMSO control (Fig. 21B). Although EBV-, BL cells did not show statistically significant 
changes in phospho-Chk1 (Fig. 20C), total Chk1 levels did show a statistically significant 
decrease at 200 µM (Fig. 21C). When comparing the phospho/total ratios for Chk1, 
EBV+, BL cells showed decreased ratios at higher concentrations (175 and 200 µM), 
EBV+, non-BL showed increased and decreased ratios throughout different 
concentrations, and EBV-, BL cells showed increased ratios with increasing 
concentrations at 175 and 200 µM (Fig. 22). Ratio results suggested that CPO exposure 
caused overall decreased production of Chk1 in EBV+, BL whereas EBV-, BL cells 
showed increased production of Chk1 at high concentrations. Since we saw changing 
levels of Chk1, we were also interested to see if Chk2 levels showed a similar trend and 
to see if the ATM/Chk2 side of DDR was also activated.  
Here, we only probed Western blots for phosphorylated Chk2. EBV+, BL cells 
exposed to CPO showed statistically-significant increases of phospho-Chk2 levels at 100 
µM, 125 µM, and 200 µM when compared to the DMSO control (Fig. 23A). Similarly, 
EBV+, non-BL cells showed increased levels of phospho-Chk2 with statistical 




significant difference in phospho-Chk2 levels at any dose of CPO, although there was a 
general trend of increasing phospho-Chk2 with increasing dose (Fig. 23C). We did not 
look at total levels of Chk2, though it would be of interest to us to see if total levels 
increased, decreased, or stayed the same so we could compare the phospho/total ratios.  
In the presence of dsDNA damage, we would expect to see increased levels of 
phospho-Chk2 (an inhibitor of Cdc25A) which would then lead to decreased CDK2 
activity, decreased cell entry into S phase, and thus eventually a G1 arrest. In turn, we 
would expect decreased levels of phospho-Chk1 (an inhibitor of Cdc25C plus an 
activator of wee1), and activated CDK1, which would allow for G2 to M transition. For 
EBV+, BL cells, we see significantly decreased phospho-Chk1 at higher doses of CPO 
along with increased levels of phospho-Chk2 at lower doses, aligning with a cell cycle 
arrest at G1 phase. With EBV+, non-BL cells, we see significantly decreased phospho-
Chk1 at lower doses of the CPO along with increased levels of phospho-Chk2 at slightly 
higher doses, supporting a scenario where there is a more likely progression into S phase, 
along with transition into M phase. In contrast, EBV-, BL cells showed little change in 
phospho-Chk1 and –Chk2 levels. Taken together, the presence of the virus may 
predispose B cells to cell cycle deregulation in the presence of the pesticide, leading to 
cell cycle abnormalities. Once more, we saw evidence that the presence of EBV changed 














Figure 20. CPO Exposure Decreased Phosphorylated Chk1in B Cells. (A) EBV+, BL, 
(B) EBV+, non-BL, and (C) EBV-, BL cells were treated with CPO for 24 hours. P-
Chk1was standardized to the loading control (𝛽� Actin) and treatments were compared 









Figure 21. CPO Exposure Decreased Total Chk1 Protein Levels. (A) EBV+, BL, (B) 
EBV+, non-BL, and (C) EBV-, BL cells were treated with CPO for 24 hours. Total 
Chk1was standardized to the loading control (𝛽� Actin) and treatments were compared 








Figure 22. Phosphorylated and Total Chk1 Ratios. (A) EBV+, BL and (B) EBV-, BL 
cells were treated with CPO for 24 hours. The phosphorylated and total levels of Chk1 










4. Discussion and Conclusions 
 Previous work (Chapter 2), showed CPF exposure of EBV+ and EBV- B-
lymphocyte cells decreased cell viability, caused dysregulation of the cell cycle, altered 
levels of important EBV replication proteins (BZLF1 and EBNA-1), and caused changes 
to levels of important cellular proteins like p70S6K and YY1. These results were 
particularly interesting since there appeared to be some level of viral effect, where cells 
that were EBV- showed a more sensitive response to CPO exposure in comparison to 
EBV+ cells. That is, EBV appeared to have a protective effect on the CPO exposed host 
Figure 23. CPO Exposure Increased Phosphorylated Chk2 in B Cells. (A) EBV+, BL, 
(B) EBV+, non-BL, and (C) EBV-, BL cells were treated with CPO for 24 hours. P-
Chk2 was standardized to the loading control (𝛽� Actin) and treatments were compared 




cell. Therefore, we wanted to further explore what contributed to some of the effects that 
we observed. We hypothesized that oxidative stress and the DNA damage response 
signaling pathway could be contributing factors to the effects we observed in Chapter 2. 
We used H2-CMDCFDA (for general oxidative stress), TUNEL assay, and Western blot 
data to assess this hypothesis and to better understand how CPO affects EBV-host/cell 
interactions.  
 Studies have shown that CPF and CPO exposure can induce oxidative stress in 
different tissues (spleen, kidney, brain, and liver of rats)162 and cell types (neuroblastoma, 
blood, and oligodendrocyte progenitor in humans, erythrocytes and neurons in 
mice).2,89,127,163–167 Our results showed that only EBV+, BL cells showed a statistically-
significant increased presence of oxidative stress at high concentrations of CPO. Even 
though EBV+, non-BL cells exposed to CPO did not show any statistically significant 
changes in oxidative stress, the results still showed a trend of increasing oxidative stress 
at high concentration of CPO exposure. EBV-, BL cells on the other hand, did not show 
any significant changes to oxidative stress. Together, this indicated that the presence of 
both EBV and CPO may have elicited a potentiated effect with each other to increase the 
production of reactive oxygen species and eventual oxidative stress. Additionally, results 
indicated, regardless of statistical significance, that all treatments exhibited some level of 
oxidative stress.  
Literature also supports that in rat and human peripheral lymphocytes, 
organophosphate (including CPF) exposure induced DNA damage.168,169 With the 




statistically-significant changes in DNA damage; however, both EBV+, BL and EBV-, 
BL cells did show that CPO and CPF exposure resulted in some DNA damage. This 
lower level of damage could be explained by the fact that B-lymphocyte cells are not the 
targets for CPF or CPO and thus, the response that B cells have to CPO exposure, in 
comparison to neurons, is not as robust. We also did not expect to observe great amounts 
of DNA damage as our data indicated CPO caused few changes in cell viability (Chapter 
2). Additionally, it was interesting to compare oxidative stress and DNA damage results 
since EBV+, BL cells showed evidence of increasing oxidative stress, but not DNA 
damage while EBV-, BL cells showed no change of oxidative stress, but most were 
responsive to DNA damage. It was likely that DNA damage was not the main mechanism 
that was affected by oxidative stress, even though we have shown evidence that the DDR 
pathway is in some way activated. Lipid peroxidation, which can be also be triggered by 
oxidative stress, may have played a role in the effects that we saw in Chapter 2. Also it is 
likely that a combination of oxidative stress, DNA damage, and lipid peroxidation were 
contributing factors to cell viability, cell proliferation, cell cycle related changes when B-
lymphocytes were exposed to CPF or CPO. Regardless, it was still interesting to see that 
with the little DNA damage produced by CPF and CPO, EBV+ and EBV- cells showed 
activation of proteins associated with the DDR pathway.  
The presence of ssDNA or dsDNA breaks via oxidative stress is known to trigger 
the DDR signaling pathway by activating ATM (Ataxia-telangiectasia mutated) or ATR 
(ATM-and Rad3-Related).100,104,152,154 As our results showed the presence of oxidative 




pathway was activated. We found EBV+, BL and EBV-, BL cells showed a trend of 
decreasing (but yet still activated) phospho-ATR and total ATR levels with higher CPO 
concentrations. This suggested that at lower CPO doses, oxidative stress associated 
DNA-damage functions through ATR (due to the presence of ssDNA). In contrast, at 
higher CPO doses, DDR may be activated via ATM (due to dsDNA breaks). Given our 
results, we can further explain and understand our results from Chapter 2.  
In our previous study (Chapter 2), we observed changes in cell cycle regulation 
when cells were exposed to CPF and CPO, suggesting that the presence of this 
organophosphate may play a role in cell cycle progression. Zhao et al. also found similar 
results when they exposed EBV+, BL cells to CPF for 4 hours.128 In our study, with 
additional cell lines, concentrations, and the addition of the active metabolite (CPO), we 
observed statistically significant data points supporting a model where CPO altered cell 
cycle regulation to induce a G1/S transition arrest. Interestingly, when we investigated 
the protein levels of cell cycle checkpoint regulators (Chk1 and Chk2), we observed a 
statistically-significant decrease in phospho-Chk1 and increase in phospho-Chk2 levels. 
We observed that phospho levels of Chk1 and Chk2 in EBV+ cells were affected by the 
CPO more so than the EBV- cells, suggesting the presence of the virus influenced 
cellular behavior when exposed to CPO. We also observed that decreased phospho and 
total Chk1 levels corresponded to decreased phospho- and total ATR levels. Taken 
together we believe it is possible that both ATR and ATM pathways were likely activated 





the ATM pathway was favored. Overall, these results provided further support that CPF 
and CPO exposure induced cell cycle arrest at the G1/S transition in EBV+ and EBV- 
cells.  
 When we take the cell cycle, oxidative stress, DNA damage, and the cell cycle 
checkpoint protein data together, we can better understand how CPO interacts with EBV 
and B-lymphocytes in relation to oxidative DDR mechanisms. In EBV+, BL cells, we 
believe that at lower concentrations, CPO produced low levels of oxidative stress to 
induce small amounts of DNA damage to trigger the ATR response, as we observed 
increased levels of phospho-Chk1. However, at higher concentrations (175 and 200 µM 
of CPO), we believe there was a switch from ATR activation to ATM activation. 
Although we did not have ATM protein level-data, there was a dramatic decrease of 
phospho-Chk1 levels at 175 and 200 µM of CPO exposure, an increase of p-Chk2 levels 
as CPO exposure increased, and a decrease in phospho-ATR levels. This agrees with our 
cell cycle data where EBV+, BL cells appeared to have a G1/S transition arrest; the 
activation of ATM and Chk2, and the subsequent deactivation of Cdc25A/C and CDK2 
result in a G1/S transition arrest. Given only having oxidative stress, Chk1, and Chk2 
data, we can speculate that EBV+, non-BL cells behave similarly to EBV+, BL cells 
resulting in ATM and Chk2-mediated DDR. However, this does not necessarily 
correspond with our cell cycle data from Chapter 2 since increasing CPO exposure did 
not result in cell cycle arrest at the G1/S transition; the number of cells actually increased 
as CPO doses increased. Though it’s possible that there was a cell cycle arrest at the S/G2 




comparison, we believe EBV-, BL cells experienced enough oxidative stress, despite 
seeing little to no change of oxidative stress (perhaps inducing some other type) with 
increasing CPO doses, to trigger a mainly ATM mediated DNA-damage response since 
we saw an overall trend of increased levels of phospho-Chk2. Again it is important to 
note that Chk1 and Chk2 can both be active since double strand DNA breaks can form 
single strand break intermediates,98,109 as we saw in the EBV-, BL cells.  
 Our study further investigated how virus-host/cell interactions are affected when a 
potentially toxic, exogenous environmental factor is introduced into a system. Our 
findings showed that the presence of increasing CPO doses varied in exhibiting oxidative 
damage and genotoxic stress, depending on whether the B-lymphocyte cell line was 
infected with EBV or not. We also found that EBV+, BL cells potentially showed an 
ATR-mediated DNA-damage response at lower concentrations of CPO, then switched to 
mainly an ATM-mediated DNA-damage response and cell cycle arrest. EBV+, non-BL 
cells demonstrated a more interesting behavior where cells exhibited similar patterns seen 
in EBV+, BL cells, but did not result in evident cell cycle arrest at the G1/S transition. 
The EBV-, BL cells appeared to be acting through an ATM-mediated response despite 
not having an overabundance of oxidative stress and genotoxic stress. Similar to our 
previous study, it appears that EBV+ cells respond differently when compared to EBV- 
cells. This suggests that presence of EBV plays a role in B-lymphocyte regulation and 
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DISCUSSION AND CONCLUSIONS 
 
 
1. Overall Discussion and Conclusions 
 This dissertation investigated the organophosphate pesticide, chlorpyrifos (CPF) 
and its active metabolite chlorpyrifos-oxon (CPO), and its effects on B-lymphocyte cells 
infected with and without the ubiquitous Epstein-Barr virus (EBV). We were interested in 
whether or not CPF and CPO exposure altered virus-host interactions both at the viral and 
cellular level and what mechanisms were driving these effects. Using EBV+, BL, EBV+, 
non-BL, and EBV-, BL cells, we were able to see how the presence of both EBV and the 
organophosphate affected cellular and viral replication and the mechanisms that drove 
these processes. Visual result summaries of the dissertation for both EBV+, BL, EBV+, 
non-BL, and EBV-, BL can be seen in Figures 24 and 25.  
In unperturbed cells, we can assume that most cellular processes are functioning 
normally and in the presence of potential danger, cellular mechanisms would activate to 
protect and repair the cell. We found that CPF induced cytotoxicity to decrease cell 
viability in EBV+, non-BL and EBV-, BL cells, but not EBV+, BL cells. Interestingly, 
none of the cell lines showed any significant changes in cell viability when cells were 
exposed to CPO. Overall, this suggested that CPF may produce more immediate 
cytotoxic effects on cells even though CPO, as the active metabolite, is more toxic. 




(CPF is a neurotoxin)61,76,87 cell type in contrast to B-lymphocytes. Thus, the effects we 
see in our results may not be as robust as they would be if we used neuronal or brain 
cells. Alternatively, CPF and CPO may have different molecular targets when binding to 
acetylcholine receptors which may have changed the toxicity of the organophosphate. 
Although CPO may not be causing direct cytotoxic effects to cause cell death, the active 
metabolite may alter other cellular functions to cause defects or dysregulation in 
important pathways like the cell cycle since we did see CPF and CPO affect total cell 
concentrations with increasing concentrations of the pesticide.88,170 
 To investigate putative organophosphate-mediated irregularities in cellular 
mechanisms, we decided to examine the cell cycle to determine if CPF and CPO 
exposure induced cell cycle arrest or if exposure induced cells to progress through cell 
cycle phases. In unperturbed cells, we would expect the cell cycle to aid in cell 
proliferation of healthy cells and regulate and undergo proper defense and repair 
mechanisms (activation of tumor suppressor proteins, deactivation of oncoproteins, and 
cell cycle arrest to allow time for repair) in the presence of genotoxic or cytotoxic 
factors.94,102,159 EBV+, BL, EBV+, non-BL, and EBV-, BL cells were exposed to CPF 
and CPO for 24 hours then assessed for cell cycle progression in G1, S, and G2 phases. 
We found that CPF exposure in all cell lines, at the highest dose (300 µM), showed 
decreased number of cells in G2 phase, which suggests that this high dose induced a G1/S 
transition arrest. CPO exposure on the other hand exhibited interesting results given that 
we observed statistically significant results at lower CPO concentrations. Overall, EBV+, 




BL cells, though the evidence of cell cycle arrest in EBV-, BL cells was more apparent at 
lower concentrations of CPO. EBV+, non-BL cells on the other hand, did not show clear 
evidence of any type of cell cycle arrest. In fact, at certain CPO doses, the number of 
cells entering S phase increased. One possible explanation would be that cell cycle 
checkpoints were altered to prohibit an arrest, or the cells were undergoing an S/G2 
transition arrest since we did see decreased percentage of cells in G2. These results 
suggest EBV+ cells exhibit a delayed response in cell cycle arrest (seen in EBV+, BL 
cells) or a response that promotes cell cycle progression through S phase (as seen in 
EBV+, non-BL cells), because EBV-, BL cells showed evidence of cell cycle arrest at 
lower concentrations of CPO.  
 Given that we know CPF and CPO exposure caused changes in cell viability, cell 
concentration, and the cell cycle, it was of interest to us to investigate how viral 
replication was affected, considering EBV replication and survival requires hijacking and 
utilizing the host’s cellular mechanisms.1,38 EBV immediate-early protein BZLF1 is an 
important viral protein in lytic replication. BZLF1 acts as a required trans-activator for 
EBV early proteins so that viral replication can occur,1,35,57 thus its presence is a marker 
for lytic replication. When EBV+, BL and EBV+, non-BL cells were exposed to 100 µM 
of CPF or CPO for 24 hours and chemically induced for lytic replication (using sodium 
butyrate and 12-O-tetradecanoylphorbol-13-acetate), BZLF1 levels decreased in EBV+, 
BL but increased in EBV+, non-BL cells, while both cell lines exhibited decreased 
BZLF1 levels with CPO exposure. We also examined the effects of CPO on EBV latent 




in all latency types and therefore is a marker for EBV latency. When EBV+, BL and 
EBV+, non-BL cells were exposed to different doses of CPO for 24 hours, the cells 
displayed decreased levels of EBNA-1. All together these results suggest that 
organophosphate exposure to EBV+ cells drives the virus towards latency if lytic 
replication is induced, or drives already latent cells to remain latent and not trigger lytic 
reactivation. This was further supported when we examined cellular proteins that are 
associated with the regulation of EBV replication such as YY1, which is a ubiquitous 
promotor and repressor protein, and p70S6K, a protein most notably associated with 
translation that is downstream of mTORC1.129,171 YY1 is known to bind to EBV 
promoters to repress or keep the virus in latency131; CPO exposure did not decrease levels 
of YY1 in EBV+ cells which explains the decreased levels in BZLF1 and null change in 
EBNA-1 levels. Previous studies have indicated that EBV lytic replication relies heavily 
on mTORC1 activity54,136; our results showed that phospho-p70S6K levels decreased 
with CPO exposure. Decreased levels of activated p70S6K indicate that mTORC activity 
is being inhibited by CPO and therefore helps explain decreased levels of BZLF1. 
Although EBV-, BL were not related to regulation of EBV, it was interesting to see how 
the absence of the virus actually increased levels of phospho-p70S6K.  
 After observing CPO-induced changes in both EBV and B-lymphocyte 
replication, it was then of interest to investigate potential driving cellular mechanisms 
that contributed to these results. Past literature and studies have established 
organophosphates, and specifically chlorpyrifos, are able to induce oxidative stress and 




not specifically investigate how EBV+ B-lymphocyte cells influenced cellular signaling 
pathways and cellular regulatory mechanisms in relation to cytotoxic and genotoxic 
stressors. Therefore, we examined if B-lymphocytes exhibited organophosphate-induced 
oxidative stress and DNA damage, in addition to proteins associated with these stressors.  
 EBV+, BL and EBV+, non-BL cells exposed to CPO for 24 hours overall showed 
increased presence of oxidative stress, while EBV-, BL cells did not exhibit a decrease 
nor increase of oxidative stress with increasing concentrations of CPO. This suggests that 
EBV presence and CPO exposure together caused a greater cellular response in 
comparison to only pesticide exposure. Additionally, other types of stressors may be 
affecting EBV-, BL cells when exposed to CPO. Although not statistically significant, we 
also determined CPF and CPO produced low levels of DNA-damage in EBV+, BL and 
EBV-, BL cells, which may play a role in both viral and cellular changes pertaining to 
replication such as triggering the Ataxia telangiectasia mutated (ATM)/Ataxia 
telangiectasia Rad3 related (ATR) signaling cascade to induce cell cycle arrest. Although 
the organophosphate did not produce large amounts of DNA damage, results still suggest 
that CPF and CPO exposure were still able to act as cytotoxic and genotoxic stressors in 
B-lymphocyte cells despite not dramatically affecting cell viability. To further explore 
genotoxic stressors in relation to the cell cycle, we also explored how DDR and cell cycle 
checkpoints were affected with CPO exposure. 
 In the presence of cellular stressors like DNA-damage, ATM and ATR are 
typically activated to induce checkpoint proteins Chk1 and Chk2 activity to initiate a 




DNA damage, Chk1 and Chk2 are not phosphorylated, which allows for Cdc25A/C to 
either remove a phosphate group from CDK1 or CDK2 which in turn allows for the cell 
cycle to progress.90,91 In the presence of ssDNA or double strand DNA breaks, cells 
should respond by activating ATR (single stranded DNA breaks) or ATM (double 
stranded DNA breaks) and then phosphorylate Chk1 (via ATR activation) or Chk2 (via 
ATM activation).98,100 Phosphorylation of Chk1 and Chk2 then results in the 
phosphorylation Cdc25A and Cdc25C; this phosphorylation of Cdc25s inhibits its 
activity and therefore will leave CDK1 (via ATR and Chk1) or CDK2 (via ATM and 
Chk2) phosphorylated and thus will cause cell cycle arrest.91,93,95,96,101 We found that 
CPO exposure most likely induced an ATM-mediated response via double strand DNA 
breaks in EBV+, BL and EBV-, BL cells, though ATR-mediated DNA-damage was 
likely also present because double strand breaks can produce single strand DNA 
intermediates to trigger the ATR-signaling cascade.98 This was supported by observing 
phosphorylated and total ATR levels decreasing, phosphorylated and total Chk1 levels 
decreasing, and phosphorylated Chk2 levels increasing when cells (especially EBV+, BL 
and EBV+, non-BL cells) were exposed to CPO.  
 Overall, this dissertation addressed our initial hypotheses that 1) CPF and CPO 
exposure would induce viral and host cell alterations related to replication, 2) EBV and 
CPF (and its active metabolite CPO) alter virus-host interactions to produce a combined 
effect, that is the presence of both EBV and CPF/CPO produces greater cellular responses 
in comparison to cells that are not infected with EBV, and 3) CPF and CPO exposure to 




mechanisms (such as the cell cycle) that in turn can affect EBV and B-lymphocyte 
replication. Our results suggested that CPF and CPO exposure caused alterations in EBV 
and host cell replication mechanisms with a) changes in EBV replication protein levels, 
b) likely G1/S transition cell cycle arrest, and c) changes in total cell concentration in a 
pesticide concentration dependent manner. We concluded that CPO exposure to B-
lymphocyte cells produced small amounts of oxidative stress and DNA damage and it is 
likely that other factors like lipid peroxidation may also play a role in our results. We 
speculate that this small amount of damage and stress was still enough to elicit a cellular 
response to trigger cell cycle arrest. We also speculate that CPO may have bound to non-
target receptors in comparison to CPF, where CPF caused changes in cell viability while 
CPO did not. This would explain, in part, why CPF may have reacted differently with the 
host cells and virus in comparison to CPO. Lastly, we concluded that EBV and the 
organophosphate alter virus-host interactions more so in a potentiation effect in 
comparison to a combined effect, as initially hypothesized (Fig. 26). Our results 
suggested that the presence of EBV has a protective response in favor of the virus, where 
appropriate cellular responses are delayed until cells are exposed to higher concentrations 
of CPF or CPO. In contrast, cells without the virus (EBV-, BL) are readily responding to 











Figure 24. Summary of Results when EBV+, BL and EBV+, non-BL Cells were 















































Figure 26. Revised Conceptual Model of EBV-Host Interactions and 
Organophosphate Exposure. (A) Initial model hypothesized a combined effect when 
EBV was present with the organophosphate. (B) Our revised model now illustrates the 
presence of EBV and organophosphates likely increases disease risk. Our results 
suggest the combination of these factors had a protective response for the virus and 





2. Future Directions 
To fully understand the effects of CPF and CPO on B-lymphocytes, a more in 
depth investigation of the relationship between acetylcholine and B-lymphocytes is 
needed. Although information on non-neuronal acetylcholine receptors are well 
described, acetylcholine receptors in B-lymphocytes is less defined in comparison to 
other immune cells like T cell and natural killer cells. One way to approach this is to first 
identify if acetylcholinesterase (the target for CPO) is present in B-lymphocytes. This can 
be done by probing for acetylcholinesterase via Western blot or by qRT-PCR to identify 
if transcripts are present in these cells. Similarly, it would be necessary to identify which 
type of acetylcholine receptors are present in B-lymphocytes, nicotinic or muscarinic 
receptors; this could also be done through Western blot or qRT-PCR. If acetylcholine 
receptors are detected, a colorimetric assay can detect levels of acetylcholine for cell 
suspensions, where hydrogen peroxide (the byproduct of oxidized choline from 
hydrolyzed acetylcholine) can be detected by the colorimetric probe. Knowing what type 
of acetylcholine receptor and if acetylcholinesterase is present in B cells would provide 
evidence that would determine if CPF and CPO have the same or different 
targets/receptors. Thus, may help explain differences in results between the parent 
compound and the active metabolite.  
It would also be of interest to also investigate further aspects of the cell cycle and 
cell cycle arrest. Targets downstream of Chk1 and Chk2 like the cell cycle regulators 
CDKs and components that regulate CDKs (cyclins and CDK inhibitors) would be useful 




exposure. Additionally, investigation of oncogenes, tumor suppressors and genes related 
to DNA repair would also provide evidence that the cell cycle is being affected during 
organophosphate exposure.  
 Lastly, it would be of great interest to further investigate this topic using an 
additional cell line to fully compare EBV+, non-BL results. EBV+, BL and EBV-, BL 
provides useful comparisons since both cell lines are both Burkitt’s lymphoma, so an 
additional cell line, EBV-, non-BL would be beneficial. The addition of this cell line 
would help determine if EBV-, non-BL cells showed a more sensitive response to lower 
concentrations in comparison to EBV+, non-BL cells and if the presence of EBV and 
organophosphates allows the cells to be protective of the virus and thus delays regular 
cellular responses until higher concentrations. This would indicate that EBV presence 
does play a major role in certain disease pathogenesis as the virus would disrupt normal 
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